Abstract 3504
Background
New hormonal agents (NHA) have been widely used to treat patients with metastatic and non-metastatic CRPC, with abiraterone, enzalutamide and apalutamide being FDA approved. Falls and fractures are common adverse events (AEs) observed in these patients. We conducted a meta-analysis of randomized controlled trials (RCTs) to characterize the incidence and relative risks (RRs) of falls/fractures associated with these drugs.
Methods
PubMed, Cochrane, Embase, abstracts presented at annual meeting of the ASCO and ESMO were searched for articles published from 2005 to December 2018. Eligible studies included phase II and III RCT of abiraterone, enzalutamide and apalutamide. Safety profile from selected studies was evaluated for all-grade and high-grade falls/fractures. Summary incidences and RR, with 95% confidence intervals, of all-grade and high-grade events were calculated using random-effects or fixed-effects model based on the heterogeneity of selected studies.
Results
5 RCT with adequate safety profile reporting on falls/fractures were selected and included a total of 6,695 patients. 2,500 patients received placebo/control and 4,195 patients received NHA. The incidence of all-grade falls for control arm and NHA arm was 5.0% and 10.0%, respectively. There was a significant increase in the risk of all-grade and high-grade falls with RR of 2.02 (95% CI 1.66-2.45; p < 0.0001) and 2.10 (95% CI 1.11-3.99; p = 0.0226), respectively. The incidence of all-grade fractures was 3.0% in control arm and 8.0% in NHA arm. There was a significant increase in the risk of all-grade and high-grade fractures with RR of 2.30 (95% CI 1.77-2.99; p < 0,0001) and 2.11 (95%CI 1.18-3.74; p = 0.0111), respectively.
Conclusions
NHAs are associated with higher risk of falls and fractures compared to placebo. However, it should be assessed with caution as the total observation time in the NHA arms were usually longer than with placebo. We could not investigate the mechanisms involved in falls, but we speculate that an effect in balance or fatigue/sarcopenia secondary to profound androgen deprivation may play a role. Moreover, fractures in CRPC patient population may impact quality of life and mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract